

# UPDATE ON ACUTE STROKE THERAPY ADVANCES

- The SAINT-I trial of NXY-059 is the first neuroprotective trial to demonstrate a positive outcome
- The trial used a novel approach to analyzing the Modified Rankin Score outcome at day-90
- Looking at a shift of the mRS across the whole range of the scale evaluates more subtle but clinically meaningful effects
- NXY-059 also reduced hemorrhagic risk with t-pa

# UPDATE ON ACUTE STROKE THERAPY ADVANCES

- The target of acute stroke therapy is the ischemic penumbra
- Penumbral imaging with MRI or perfusion CT targets therapy to potentially responsive patients and should help to expand the therapeutic time window
- More information is becoming available that penumbral imaging is useful for treating patients up to 9 hours from onset with t-pa and desmoteplase